ArticleJournal of clinical medicine2019
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
Abstract read
In one paragraph
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.Haematologica · 2023Pooled it
- Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection.Acta haematologica · 2026Article
- Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.Annals of hematology · 2025Article
- Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.BMC cancer · 2025Article
- Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.Annals of hematology · 2024Observational
- Multiple Myeloma in 2023 Ways: From Trials to Real Life.Current oncology (Toronto, Ont.) · 2023Review
- Low-dose decitabine plus bortezomib-dexamethasone therapy is well-tolerated and highly effective on first-relapsed multiple myeloma: a single-center phase 2 trial.American journal of cancer research · 2023Article
- Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.International journal of hematology · 2022Article
- Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.Frontiers in oncology · 2022Article
- Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.International journal of molecular sciences · 2021Review
- Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma.Cells · 2021Review
- Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.Frontiers in oncology · 2021Article
- A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents.Journal of clinical medicine · 2020Article
- Serum free light chains and multiple myeloma: Is it time to extend their application?Clinical case reports · 2020Article
- Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.Journal of clinical medicine · 2019Article
- A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?Clinical case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Concetta ConticelloDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. ettaconticello@gmail.com.
Alessandra RomanoDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. sandrina.romano@gmail.com.ORCID 0000-0002-6333-4433
Vittorio Del FabroDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. vdelfabro@yahoo.it.
Enrica Antonia MartinoDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. enricaantoniamartino@libero.it.
Valeria CalafioreDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. valeriacalaf@gmail.com.
Giuseppe SapienzaDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. sapienzagius@gmail.com.
Valerio LeottaDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. valerio_leotta@yahoo.it.
Marina Silvia ParisiDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. marinaparisi@hotmail.it.
Uros MarkovicDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. urosmarkovic09041989@gmail.com.
Bruno GaribaldiDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. brunga93@gmail.com.
Salvatore LeottaDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. leotta3@yahoo.it.
Emilia CotziaU.O.C. Ematologia, ASP8, 96100 Siracusa, Italy. cotemi@hotmail.it.
Vanessa InnaoDivision of Hematology, Dipartimento di Patologia Umana dell'Adulto e dell'Età Evolutiva, Policlinico G. Martino, University of Messina, 98122 Messina, Italy. vinnao@unime.it.
Donato ManninaU.O.C. Ematologia, Azienda Ospedaliera Papardo, 98158 Messina, Italy. donamanni@gmail.com.ORCID 0000-0001-8665-1258
Santo NeriU.O.C. Ematologia, Azienda Ospedaliera Papardo, 98158 Messina, Italy. santoneri67@gmail.com.
Maurizio MussoU.O.C. OncoEmatologia e TMO, Dipartimento Oncologico, La Maddalena, 90146 Palermo, Italy. mamusso53@gmail.com.
Renato ScaloneU.O.C. OncoEmatologia e TMO, Dipartimento Oncologico, La Maddalena, 90146 Palermo, Italy. r.scalone69@gmail.com.
Clotilde CangialosiU.O.C. Ematologia A. O. Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy. clotildecangialosi@gmail.com.
Francesco AcquavivaU.O.C. Ematologia A. O. Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy. clotildecangialosi@hotmail.com.
Giovanni CardinaleU.O.C. Ematologia, ARNAS-Civico-Di Cristina-Benfratelli, 90147 Palermo, Italy. cardinaleg@libero.it.ORCID 0000-0002-5072-2728
Anxur MerendaU.O.C. Ematologia, ARNAS-Civico-Di Cristina-Benfratelli, 90147 Palermo, Italy. anxur.merenda@arnascivico.it.
Cinzia MaugeriDivision of Hematology, Sant'Elia Hospital, 93100 Caltanissetta, Italy. maugericinzia@hotmail.com.
Giuseppina UccelloU.O.C. Ematologia, ARNAS Garibaldi, 95122 Catania, Italy. giusy83@virgilio.it.
Massimo PoidomaniSIMT Hematology, ASP7, 97100 Ragusa, Italy. massimo.poidomani@asp.rg.it.
Giuseppe LongoU.O.C. Ematologia, Ospedale San Vincenzo, 98039 Taormina (ME), Italy. longo_giuseppe@hotmail.com.
Melania CarlisiU.O.C. Ematologia, Policlinico P. Giaccone, 90127 Palermo, Italy. melania.carlisi@unipa.it.
Daniele TibulloDepartment of Biomedical and Biotechnological Science, University of Catania, 95125 Catania, Italy. d.tibullo@unict.it.
Francesco Di RaimondoDivision of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. diraimon@unict.it.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
KRd regimenmultiple myelomasalvage therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.